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Herd protectionBackground and aim of the work: In 2010 PCV13 replaced PCV7 in the pediatric vaccination schedule for
Italian children. While a strong herd effect was demonstrated for PCV7, a possible herd effect due to
PCV13 is still under debate. Our aim was to evaluate differences in the distribution of pneumococcal ser-
otypes between the pre and post-PCV13 eras in unvaccinated Italian adolescents and adults with
laboratory-confirmed pneumococcal infection from 3 Italian Regions with a high rate of PCV13 vaccina-
tion of children.
Patients and methods: Adolescents and adults admitted with laboratory-confirmed pneumococcal infec-
tion in the hospitals of 3 Italian Regions (Friuli-Venezia Giulia, Emilia Romagna, and Tuscany) between
April 2006 and June 2016 were included in the study. Diagnosis of pneumococcal infection and serotyp-
ing were performed with Real Time PCR directly on normally sterile fluids or on culture isolates.
Results: 523 patients with laboratory-confirmed pneumococcal infection were enrolled (Male/Female
ratio was 300/223, 1.3; median age 67.1, IQR 53.4–74.9). None of the patients had been vaccinated with
any pneumococcal vaccine; 96.4% were serotyped. Overall, the most frequent serotypes were 3 (67/504,
13.3%), 8 (43/504, 8.5%), and 19A (38/504, 7.5%). Serotype distribution differed among age classes and
clinical presentations.
Overall, PCV13 serotypes accounted for 47.6% of cases: 62.3% in the pre-PCV13 era and 45.0% in the post-
PCV13 era; (p = 0.005 OR = 2.03; CL 95%: 1.2–3.3). Serotype 7F accounted for 12/77 (15.6%) of all sero-
types in the pre-PCV13 period and for 12/427 (2.8%) in the post-PCV13 period and was the only serotype
significantly contributing to the difference in percentage between pre and post-PCV13 eras.
Conclusion: Our study demonstrated a difference in percentage in serotype distribution in adolescents
and adults laboratory-confirmed pneumococcal infection between the pre and post-PCV13 eras. This dif-
ference is mainly due to the decrease of serotype 7F. Thus, in order to decrease disease burden, adults and
in particular the elderly should be offered a specific vaccination program.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Despite the availability of effective vaccines, Streptococcus pneu-
moniae continues to be the leading cause of pneumonia and inva-
sive bacterial infections, in particular in elderly people and in
children. Over 90 serotypes are known but only a subset causes
the majority of pneumonia and invasive pneumococcal diseases
(IPD). Streptococcus pneumoniae is also a common commensal
inhabitant of the nasopharynx of healthy people, especially young
children who, consequently, can transmit the pathogen to adults
F. Nieddu et al. / Vaccine 35 (2017) 1544–1550 1545[1]. Nasopharyngeal colonization is considered an essential step to
bacterial spreading and subsequent IPD.
Pneumococcal incidence, virulence, as well as circulating sero-
types differ among countries and may vary in different periods in
the same country [2]. These changes are caused both by selective
pressure caused by vaccination and by secular trends [3]. Wide-
spread vaccination with the 7 valent conjugate pneumococcal vac-
cine (PCV7) was highly effective in reducing IPD in vaccinated
children and induced a significant decrease of IPD in unvaccinated
adults as well [4–7]. Since 2010, 13-valent conjugate pneumococ-
cal vaccine (PCV13) has replaced PCV7 in Italy and in over 120
other countries and has been included in pediatric vaccination
schedules. In 2012, PCV13 was approved for use in adults over
50 years of age in Italy and in other countries. In 2013 PCV13
was approved for all ages. Since 2015, PCV13 has been recom-
mended not only for children and high-risk groups but also for
adults aged >65 in a limited number of Italian Regions.
Several studies demonstrated strong herd protection of adults
after the introduction of PCV7 in pediatric vaccination programs,
and other studies demonstrated a similar herd protection of adults
after the introduction of PCV13 vaccination [4–6,8]. A number of
studies have addressed the serotype distribution of adult IPD in
different countries, and demonstrated serotype changes in the
short term (1–3 years) between the pre and post-PCV13 eras. How-
ever, data regarding long-term serotype changes in adult and
elderly IPD in the post-PCV13 era is still incomplete. That informa-
tion is especially interesting and significant for Italy, one of the
‘‘super-aging” societies of the world, with a 21.2% of population
>65 years in 2014, according to the Organization for Economic
Co-operation and Development (OECD) [9].
Therefore, the aim of the present work was to evaluate the
presence and the extent of PCV13 herd protection on laboratory-
confirmed pneumococcal infection in unvaccinated Italian adoles-
cents and adults 6 years after the introduction of PCV13 in Italy
and to assess serotype changes between the pre and post-PCV13
eras in Italian adolescents and adults with laboratory-confirmed
pneumococcal infection.
2. Materials and methods
2.1. Study design
This observational study was conducted from April 2005
through June 2016 in adolescents and adults (>14 years of age)
admitted with a diagnosis of pneumococcal infection to hospitals
in 3 Italian Regions. The 3 Regions (Friuli-Venezia Giulia, in the
north-east, and Emilia Romagna and Tuscany, in the center of Italy)
have very low and similar rates of polysaccharide pneumococcal
adult vaccination (<10%). PCV7 had been progressively introduced
since 2003 in Italy. The vaccine shift from PCV7 to PCV13 for chil-
dren’s vaccination was carried out in the 3 Regions in July 2010.
The pneumococcal conjugated vaccine PCV13 is offered to all
infants in those three Regions, and – according to the most recent
survey performed in 2013 – the average vaccination rate is >70%
(74.9% for Friuli, 94.1% for Emilia Romagna, and 93.5% for Tuscany)
[10]. Clinical information was collected using a standardized ques-
tionnaire defining sex, age, clinical data, and pneumococcal vacci-
nation. Stored samples (non-culturable lyophilized pneumococcal
isolates), if available, were also accepted and associated clinical
information was retrieved for clinical reports.
The study obtained the approval of the local Ethical Committee.
2.2. Laboratory methods
Clinical materials were obtained as part of standard care from
patients included in the study; more than one specimen for patientcould be available (blood, 356 samples, cerebrospinal fluid, 84 sam-
ples, pleural fluid, 22 samples, peritoneal fluid, 2 samples, articular
fluid, 1 sample) or bronchoalveolar lavage (BAL, 76 samples).
Laboratory-confirmed pneumococcal infection was defined as
the clinical suspicion of bacterial disease (pneumonia, meningitis,
sepsis, other) and the laboratory confirmation of the presence of
S. pneumoniae in a normally sterile fluid or bronchoalveolar lavage.
Laboratory confirmation was obtained by Realtime-PCR (RT-
PCR) and/or culture methods as previously described [11,12].
Whole blood and/or other biological fluids, when appropriate, were
collected from all patients as soon as possible after hospital
admission for culture and/or molecular tests. For culture purposes,
4–6 mL of blood samples (up to 3 sets) were drawn and immedi-
ately sent to the local laboratory. Standardized procedures were
used for collection and shipment of biological samples to local lab-
oratories. Samples for molecular tests were sent by the participant
centers on a voluntary basis to our Laboratory (Immunology Labo-
ratory, Anna Meyer Children’s University Hospital, Florence, Italy)
at room temperature using an overnight freepost carrier and
molecular tests were performed within 2 h of delivery. Stored iso-
lates were also accepted.
All samples were tested with RT-PCR for the lytA gene as previ-
ously described [12]. Isolates already classified as S. pneumoniae by
cultural methods were also sampled and analyzed for the lytA gene
in order to confirm the diagnosis. A sample was considered nega-
tive if there was no increase in fluorescent signal before RT-PCR
cycle 40. All samples were serotyped using RT-PCR.
For both diagnosis and serotyping by RT-PCR, 200 µL of avail-
able biological fluids or lyophilized isolates [13] were used.
For serotyping, 33 primer/probe sets targeting different regions
of the cpsA gene were used, specific for 33 different serotypes.
Twenty-nine primer-probe sets were previously published by our
group [12,14,15]. The sequences of the 4 additional primer-probe
sets are available upon request. Pneumococcal serotypes were clas-
sified as covered by PCV13 vaccines if they were included in the
13-valent (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19A) conju-
gate vaccine.
If no increase in fluorescent signal was observed after 40 cycles
for any of the serotype-specific primer/probe sets, in spite of a
positive result with both RT-PCR (lytA gene) and end-point PCR
(cpsA gene) [12], the sample was considered non-typeable with
the serotype-specific primers in RT-PCR.2.3. Statistical analysis
Two tailed p values were used and p values <0.05 were consid-
ered statistically significant. Results were expressed as means and
standard deviations (SD) or as median and interquartile range
(IQR) as appropriate. The v2 test was used to assess group differ-
ences in categorical variables. Data were processed with the SPSSX
statistical package (SPSS 11.0, SPSS Inc., Chicago, IL).3. Results
3.1. Diagnosis of pneumococcal infection
We identified a total of 523 patients, 89/523 pre-PCV13, 434
post-PCV13, 125/523 (6/125 pre-PCV13, 119/125 post-PCV13)
from Friuli-Venezia Giulia, 84/523 (5/84 pre-PCV13, 79/84 post
PCV13) from Emilia Romagna, and 314/523 (78/314 pre PCV-13
236/314 post-PCV13), from Tuscany in the period April 2006–June
2016. The 3 Regions are situated in the center or north of Italy and
represent 16% of the Italian population >14 years.
The gender ratio M/F was 300/223, 1.3; age range was
14–94 years of age; median age and interquartile range (IQR) were
Table 1
Distribution of enrolled patients according to age.
Age groups Pre-PCV13
n (%)
Post-PCV13
n (%)
Tot
14–18 8 (9.0%) 7 (1.6%) 15
19–30 4 (4.5%) 19 (4.4%) 23
31–45 13 (14.6%) 35 (8.1%) 48
46–60 16 (18.0%) 93 (21.4%) 109
61–75 30 (33.7%) 180 (41.5%) 210
76–100 18 (20.2%) 100 (23.0%) 118
Tot 89 434 523
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Fig. 2. Potential serotype coverage before (2005–2010) and after (2011–2016) the
introduction of PCV13.
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groups is shown in Table 1. None of the patients had a pneumococ-
cal vaccination history (either conjugate or polysaccharide).
Pneumococcal serotype or serogroup was identified in 504/523
patients (96.4%). In particular, for serogroup 6, 11, 12, 15, 18, 22,
33, only serogroup and not serotype was detected.3.2. PCV13 potential coverage and serotype distribution of laboratory-
confirmed pneumococcal infection
Potential coverage (defined as the percentage of laboratory-
confirmed pneumococcal infection due to serotypes included in
PCV13) in the pre-PCV13 period was 62.3% (48/77), with a signifi-
cant diminution to 45.0% (192/427) in the post-PCV13 period
(p = 0.005 OR = 2.03; CL 95%: 1.2–3.3) (Fig. 1). The potential cover-
age for PCV7 serotypes and for 6 additional PCV13 serotypes was
19.0% (96/504) and 28.6% (144/504) respectively (Fig. 1). The
potential serotype coverage of PCV13 trend year by year is shown
in Fig. 2.
Overall, the most frequent serotypes were serotype 3 (67/504,
13.3%), 8 (43/504, 8.5%), 19A (38/504, 7.5%), 12 (33/504, 6.5%),
and 22 (28/504, 5.6%). Serotypes that showed the greatest increase
in percentage in the post-PCV13 era were 8 (+5.5%), 23A (+4.4%)
and 33 (+3.5%). On the other hand, serotypes that showed the
greatest reduction in percentage in the post-PCV13 era were
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Potential coverage is different in different ages (Fig. 3A). Sero-
type 3 was the most frequent serotype in patients >45 years
(18/104, 17.3% in 46–60 years; 27/203, 13.3% in 61–75 years and
13.7%, 16/117 in >76 years) while the most frequent serotypes in
younger patients were 7F in 14–18 years patients (4/13, 30.7%),
23A in 19–30 years patients (3/21, 14.3%), and 12 in 31–45 years
patients (9/46, 19.6%).
According to the Hospital Discharge Register (HDR), sepsis was
the most frequent pneumococcal infection n = 247/523 (47.2%).
Pneumococcal pneumonia was documented in n = 169/523
(32.3%) HDR (82/169, 48.5%, were bacteremic pneumococcal pneu-
monia). Meningitis was present in n = 94/523 HDR (18.0%) (in
43/94, 45.7% cases, meningitis was associated with sepsis and in
2/94, 2.1%, with pneumonia). In one HDR, sepsis was associated
with both meningitis and pneumococcal pneumonia. In 12/523
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F. Nieddu et al. / Vaccine 35 (2017) 1544–1550 1547arthritis and otomastoiditis with sepsis, were found. Sepsis was the
most frequent pneumococcal infection in any age group with the
exception of the 14–18 years group where pneumonia was the
most frequent pneumococcal infection. Meningitis was the least
frequent pneumococcal infection in all age groups. Potential cover-
age for PCV13 according to clinical presentation is shown in Fig. 3B.
Serotype 3 was the most frequent serotype in pneumonia (30/161;
18.6%) and meningitis (10/92, 10.9%), while serotype 8 was the
most common in sepsis not associated with other clinical condi-
tions (28/241, 11.6%).
3.3. Crucial role of serotype 7F
Serotype 7F accounted for 12/77 (15.6%) in the pre-PCV13
period and for 12/427 (2.8%) in the post-PCV13 period (Fig. 1). Ser-
otype 7F represents the only statistically significant difference in
the distribution of pneumococcal serotypes between the pre and
the post-PCV13 eras. Differences in the distribution of other sero-
types were not significant, independently of the discrepancy of
sample size between the pre and the post-PCV13 eras (Fig. 4).
4. Discussion
The study demonstrates that serotype percentage changes
occurred after the introduction of PCV13 in the 3 Italian
regions studied, but herd protection, if present, is mainly due to
a significant reduction of serotype 7F. Similar results were foundby other groups [16–22] but, up to now, the crucial role of 7F
had not been clearly demonstrated. However, both in our study
in Italy and in Kendall’s study in Utah, USA, [20], the PCV13 ‘‘herd
effect” was essentially due to serotype 7F.
It is unlikely that the decrease in 7F incidence is due to a
stronger immunogenicity of that serotype in vaccinated children.
Actually, Jackson et al. demonstrated that 7F OPA titers were sim-
ilar to those induced by other PCV13 serotypes and even lower if
compared to serotype 19A, 4, 6B, 18C and 23F [23].
It is also unlikely that the 7F decrease is due to the elimination
of serotype 7F from the nasopharynx of vaccinated children. It is
well known that the herd protection induced by PCV7 is due to
the reduction of vaccine strains in the nose and in the pharynges
of vaccinated children [24,25]. Actually, we have recently demon-
strated [26,27] that in the pre-vaccination era, serotype 7F was
very rarely found (less than 1%) in nasopharyngeal swabs of Italian
children from the same Regions. So it seems quite unlikely that the
elimination of a serotype that is very rare in children’s pharynx
would give a strong herd protection to adults.
Further studies will be necessary to evaluate whether the
reduction of 7F-associated pneumococcal infection in adults may
be due to the decrease of children IPD more than 7F carriage in
children.
It should be considered that 7F reduction in percentage in
unvaccinated adolescents and adults might be due to other factors,
such as secular trends, more than being dependent on the herd
effect associated with the PCV13 vaccination of children. Actually,
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Catalonia, Spain, a region where the vaccine was only available
in the private market, with a PCV13 estimate vaccination of 55%
of children [28]. Moreover, a recent work, performed on a limited
number of cases over a 30-year period in Italy, demonstrated the
absence of that serotype in the previous decades, thus suggesting
a spontaneous oscillation of 7F incidence [29].
Our data suggest that in those countries, such as Italy, where
the only decreasing serotype is 7F, herd protection obtainable with
PCV13 is very limited, if ever present.
As in other studies, the present work showed that the most fre-
quent serotype was 3, followed by 8 and 19A. Those serotypes,
taken together, account for about one third of all laboratory-
confirmed pneumococcal infection. Similar findings have been
reported across European countries: in Navarre, Spain, 3 and 19A
were the most frequent serotypes in 2010–2013, followed by 7F
[21]. Similar results were obtained in Norway [22]. Although sev-
eral studies, both in United States and in Europe, [17,21,30,31]
demonstrated an overall herd effect of PCV13 introduction in
adults and elderly, in our study, as previously outlined, a limited
change in percentage, with the exception of 7F, occurred among
PCV13 serotypes between the pre-and post-PCV13 eras in adult
pneumococcal infection.
As specified, in the present work serogroup 6 was not split for
6A/6B and serogroup18 was not split for its serotypes. This might
lead to underestimation of the herd effects: for serotype 6 because
herd effects for PCV7 serotypes may already have been maximized
and for serotype 18 because non-PCV13 serotypes may be
included.
Our unpublished data on pediatric surveillance, consistently
with results obtained all over the world [30,32–37] on children
vaccination effectiveness, indicated a rapid and substantial declineof pneumococcal infection due to all serotypes included in PCV13,
with zero cases of 19A (that was >20% in the pre-PCV13 era) in
2015 and in the first six months of 2016 in vaccinated children.
On the other hand, as far as carriage is concerned, recent studies
performed in France suggest a permanence of vaccine serotypes
in carriers after the PCV13 vaccination [38]. Those results are not
dissimilar from what we demonstrated in 2014 [26,27]: actually,
our data demonstrated that the disappearance of PCV7 serotypes
from the nasopharynx after the vaccination is only partial and
temporary. Moreover, the 6 additional serotypes included in
PCV13 (1, 3, 5, 6A, 7F, 19A) are rarely found in carrier children.
Consequently, the limited indirect protection of adults by
vaccination of children could be expected and dedicated programs
of vaccination of adults seem the only feasible strategy.
A new, larger formulation of conjugate pneumococcal vaccines
is under preparation and will probably include 22F and 33, which
accounted for about 10% of IPD cases in adults in the US in 2007
[39]. Both of these serotypes are not commonly found in Italian
adults with IPD: 22F has decreased in the last 6 years and is now
5.1%, while serotype 33 was absent in the pre-PCV13 era and is
now 3.5%.
Our study has some limitations. The main bias and limit of the
study is related to absolute numbers of isolates before and after
PCV13 (77 pre-PCV13 and 427 post-PCV13) due to a better moni-
toring after 2010. Therefore, absolute numbers of PCV13 serotypes
are generally higher after than before vaccination. Anyway, we can
suppose that poorer surveillance before vaccination did not
influence serotype distribution. Another limitation was that our
study population was obtained from three Italian regions only,
which together correspond to about one sixth of the entire Italian
population. However, these regions have a highly vaccinated
child population (P75% of vaccinated children), compared to most
F. Nieddu et al. / Vaccine 35 (2017) 1544–1550 1549Italian regions and other countries. Consequently, the study is well
generalizable to regions with high vaccination rates in children.
Another limitation for generalizability is the low vaccination rate
in adults.
Actually, since there was a difference in vaccine uptake
between regions (minimum 74.9%, maximum 94.1%, difference
19.2%), it would be interesting to know if there were differences
in serotypes distribution in pre- and post-PCV13 vaccine period
in particular regions. However, given the limited number of iso-
lates obtained in the pre-PCV13 era, only aggregate analysis of
the 3 regions has been possible.
Another limitation was that samples were sent by the partici-
pant centers to our laboratory on a voluntary basis, so that the
study cannot give data on IPD incidence or burden of disease on
the adult population. However, the present study, performed on
a large population of Italian adolescents and adults, represents,
to our knowledge, the largest study on pneumococcal infection in
Italian adults in the last decades and, for the first time, character-
izes long-term serotype changes after the introduction of PCV13.
Pneumococcal pneumonia cases are probably underestimated
since most pneumonia are usually cured by family practitioners
and even in cases admitted to hospital, microbiological tests are
not always performed. However, we believe that cases we
described may be representative of pneumococcal serotype
distribution in the studied Italian Regions, since our data set is
the largest available in Italy, being even larger than datasets
obtained on pneumonia by the National Institute of Health through
pneumococcal surveillance [40].
Regarding clinical presentation, our study demonstrated that
about 55% of pneumonia cases were caused by PCV13 serotypes
(Fig. 3B). That is a very important finding, in light of the fact that
pneumococcal pneumonia is one of the most frequent and serious
clinical presentations of pneumococcal disease in older adults. For
that reason, adult vaccination could be a very important tool in
reducing the burden of pneumococcal infection in Italy.
5. Conclusions
Our study clearly demonstrated that the introduction of PCV13
is associated with a modification in percentage of serotypes
causing pneumococcal infection in Italian adolescents and adults.
That variation was essentially due to the strong decrease of
serotype 7F while no similar effect was seen for any other vaccine
serotype. Consequently, herd protection was probably weaker than
expected, so that it may be speculated that other factors, such as
secular trends, together with herd protection, might be the cause
for that reduction. Therefore, in order to decrease disease burden,
adults and, in particular, the elderly should be offered a specific
vaccination program. Pneumonia is the leading cause of adult
and elderly pneumococcal disease and is caused by PCV13
serotypes in about 60% of cases. Pneumonia prevention through
vaccination is particularly important for Italy, which is one of the
‘‘super-ageing” societies of the world where elderly people repre-
sent a large percentage of the total population.
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